Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2Phase NA 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Breast 1

Conditions

Breast Neoplasms 277Neoplasms 202Prostatic Neoplasms 118Polycystic Ovary Syndrome 114Colorectal Neoplasms 104Carcinoma, Hepatocellular 103Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 70Stomach Neoplasms 62Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Pain 59Neoplasm Metastasis 54Multiple Myeloma 52Pancreatic Neoplasms 46Keratosis, Actinic 46Pain, Postoperative 43Head and Neck Neoplasms 43Leukemia, Myeloid, Acute 40Leiomyoma 39Recurrence 38Liver Neoplasms 38Colonic Neoplasms 37Uterine Cervical Neoplasms 35Lymphoma 35Brain Neoplasms 34Infertility 33Papillomavirus Infections 32Ovarian Neoplasms 31Lymphoma, Follicular 31Lymphoma, Non-Hodgkin 30

Interventions

Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Chemotherapy-Induced Febrile Neutropenia × Clear all
NCT06616571 2024-09-27

Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints

Qilu Pharmaceutical Co., Ltd.

Phase 4 Recruiting
336 enrolled
BreastClassical hematology

Breast Neoplasms, Chemotherapy-Induced Febrile Neutropenia, Febrile Neutropenia

NCT03823950 2020-03-13

Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients

University of Mississippi Medical Center

Phase 4 Unknown
150 enrolled
Classical hematology

Neoplasms, Chemotherapy-Induced Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡